Female Hypoactive Sexual Desire Disorder (Women’s and Male Health) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder – Drugs In Development, 2021, provides an overview of the Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline landscape.

Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses, such as chronic renal failure, hyper-prolactinaemia and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Hypoactive Sexual Desire Disorder – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 5, 1 and 2 respectively.

Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder (Women's Health).

– The pipeline guide reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Better Life Pharmaceuticals Inc

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

Ivix Ltd

Kuhnil Pharmaceutical Co Ltd

Palatin Technologies Inc

S1 Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Hypoactive Sexual Desire Disorder - Overview

Female Hypoactive Sexual Desire Disorder - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development

Better Life Pharmaceuticals Inc

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

Ivix Ltd

Kuhnil Pharmaceutical Co Ltd

Palatin Technologies Inc

S1 Biopharma Inc

Female Hypoactive Sexual Desire Disorder - Drug Profiles

(buspirone hydrochloride + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(sildenafil citrate + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepirone hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGSN-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Hypoactive Sexual Desire Disorder - Dormant Projects

Female Hypoactive Sexual Desire Disorder - Discontinued Products

Female Hypoactive Sexual Desire Disorder - Product Development Milestones

Featured News & Press Releases

May 04, 2021: Palatin announces U.S. patent term extension for Vyleesi (bremelanotide injection)

Mar 24, 2021: Daré Bioscience announces initiation of phase 2b RESPOND study of sildenafil cream, 3.6% in women with female sexual arousal disorder

Jan 05, 2021: Ovoca Bio announces resubmission of Marketing Authorisation Application with Russian Ministry of Health for BP-101

Oct 02, 2020: Update on Marketing Authorisation application for BP-101 in Russian Federation

Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder

Dec 11, 2019: Daré Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder

Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference

Oct 16, 2019: Vyleesi phase 3 data to be presented at the 13th European Society Of Gynecology Congress

Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101

Aug 27, 2019: AMAG Pharmaceuticals announces commercial availability of Vyleesi (Bremelanotide Injection)

Aug 06, 2019: Palatin Technologies to present data on Vyleesi at Canaccord Genuity's 39th Annual Growth Conference

Jun 21, 2019: AMAG Pharmaceuticals announces FDA approval of Vyleesi (Bremelanotide Injection) for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

Jun 17, 2019: Daré Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder

May 03, 2019: AMAG Pharmaceuticals presents new data on bremelanotide at the American College of Obstetricians and Gynecologists Annual Meeting

Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Female Hypoactive Sexual Desire Disorder – Pipeline by Better Life Pharmaceuticals Inc, 2021

Female Hypoactive Sexual Desire Disorder – Pipeline by Dare Bioscience Inc, 2021

Female Hypoactive Sexual Desire Disorder – Pipeline by Emotional Brain BV, 2021

Female Hypoactive Sexual Desire Disorder – Pipeline by EndoCeutics Inc, 2021

Female Hypoactive Sexual Desire Disorder – Pipeline by Fabre-Kramer Pharmaceuticals Inc, 2021

Female Hypoactive Sexual Desire Disorder – Pipeline by Ivix Ltd, 2021

Female Hypoactive Sexual Desire Disorder – Pipeline by Kuhnil Pharmaceutical Co Ltd, 2021

Female Hypoactive Sexual Desire Disorder – Pipeline by Palatin Technologies Inc, 2021

Female Hypoactive Sexual Desire Disorder – Pipeline by S1 Biopharma Inc, 2021

Female Hypoactive Sexual Desire Disorder – Dormant Projects, 2021

Female Hypoactive Sexual Desire Disorder – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports